TheraRadar
← Back
Data updated: Jul 17, 2026

SENORES PHARMS

Generics

SENORES PHARMS is a generic drug manufacturer focused on Cardiovascular, Immunology, Neurology.

1981
Since
49
Drugs
-
Trials
0
New Drugs (2yr)
Modality:

SENORES PHARMS's Key Drugs

SENORES PHARMS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

SENORES PHARMS's Recent FDA Approvals

New NDA/BLA approvals for SENORES PHARMS over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

SENORES PHARMS's Therapeutic Areas

SENORES PHARMS's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Immunology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 50%
7 drugs
Immunology 21%
3 drugs
Neurology 14%
2 drugs
Oncology 7%
1 drugs
Respiratory 7%
1 drugs

SENORES PHARMS's Top Competitors

SENORES PHARMS's closest competitors by therapeutic-area and drug-target overlap include Novartis, AstraZeneca, and Pfizer. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

SENORES PHARMS Pipeline Snapshot

Active clinical trials for SENORES PHARMS across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Cardiovascular pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling